Dana-Farber Cancer Institute, is a principal teaching affiliate of Harvard Medical School and an NCI-designated Comprehensive Cancer Center. Based in Boston, Dana-Farber is a world-renowned leader in adult and pediatric cancer treatment and scientific research.
Novel Treatment Approaches for SCLC and Future Perspectives
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in small-cell lung cancer.
SAMETA Trial Evaluates Efficacy of Savolitinib Plus Durvalumab in MET-Driven Papillary RCC
August 10th 2023The safety and efficacy achieved with the combination of savolitinib and durvalumab vs standard-of-care sunitinib or durvalumab monotherapy will be evaluated in patients with MET-driven papillary renal cell carcinoma in the phase 3 SAMETA trial.
Dr Tarantino on the Effects of Platinum Chemotherapy Shortages in Breast Cancer
August 9th 2023Paolo Tarantino, MD, discusses how the ongoing shortages of carboplatin and cisplatin in the United States are affecting patients with breast cancer and the importance of overcoming this wave of shortages and preventing this issue from recurring in the future.
Multiple Myeloma: Unmet Needs and Future Directions in Care
After discussing earlier-line use of CAR T-cell therapy in patients with multiple myeloma, the panel considers key takeaways and future evolutions in the treatment landscape.
CAR T-Cell Therapy in Multiple Myeloma: Updates from ASCO 2023 and Beyond
Before closing out their discussion on novel therapies in multiply relapsed multiple myeloma, panelists identify the evolving role of CAR T-cell therapy.
Platinum Chemotherapy Shortages Create Additional Burden for Patients With Cancer
Jacob Sands, MD, discusses how the ongoing shortages of carboplatin and cisplatin have presented new challenges to patient care, how he and colleagues at Dana-Farber Cancer Institute are navigating these shortages, and how these limitations could ultimately have an impact on patients.
2L Dosing Considerations and Management Strategies for SCLC
Expert oncologists discuss important dosing considerations and treatment management strategies for lurbinectedin and other second-line therapy approaches in small-cell lung cancer.
LAGOON and IMFORTE Trials: Data Updates and Expert Insights
A review of the LAGOON and IMFORTE trials with expert insights regarding the potential clinical implications of current and future study findings.
Data With Novel Agents Prompt Treatment Sequencing Discussions in MCL and CLL
August 3rd 2023Catherine C. Coombs, MD, and Alexey Danilov, MD, PhD, moderate a discussion on the role and sequencing of BTK inhibitors, venetoclax-based regimens, and CAR T-cell therapy in mantle cell lymphoma and chronic lymphocytic leukemia.
Combination Strategies With Bispecifics in Multiple Myeloma
Key opinion leaders on multiple myeloma reflect on the use of combination strategies with bispecifics in the multiply relapsed setting.
Patient Scenario 3: 2L Lurbinectedin Following 1L Combination IO Chemotherapy
A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.
Evolving Treatment Strategies for SCLC in the Second-Line Setting and Beyond
Panel experts discuss evolving treatment options for small-cell lung cancer in the second-line setting and beyond.
Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.
Expanding Definitions of HER2 Expression Mediate the Role of ADCs in Breast Cancer
July 26th 2023Erika P. Hamilton, MD, discusses the role of trastuzumab deruxtecan in HER2-positive and HER2-low breast cancer; the evolution of CDK4/6 inhibitors in hormone receptor–positive disease; and how genetic testing can match patients with personalized therapies and support further precision medicine research.
Bispecifics in Multiple Myeloma: Dosing and Transition of Care
A brief review of logistical considerations that play a part in selecting novel therapy for patients with multiply relapsed multiple myeloma.